Spleen News and Research

RSS
Healthcore Media launches dynamic, educational and community-oriented health website

Healthcore Media launches dynamic, educational and community-oriented health website

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

EMBL scientists identify two small RNA molecules that ensure red blood cell production

EMBL scientists identify two small RNA molecules that ensure red blood cell production

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

Genzyme signs consent decree of permanent injunction, agrees to disgorgement

Genzyme signs consent decree of permanent injunction, agrees to disgorgement

OnePath Gaucher Application available for patients with Type 1 Gaucher disease

OnePath Gaucher Application available for patients with Type 1 Gaucher disease

Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

Researchers treat undiagnosed FIM with experimental stem cell transplant

Researchers treat undiagnosed FIM with experimental stem cell transplant

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

Melanin-covered nanoparticles may protect bone marrow from harmful radiation therapy effects: Research

Melanin-covered nanoparticles may protect bone marrow from harmful radiation therapy effects: Research

Hereditary ovarian cancer patients may develop secondary tumours in liver and spleen

Hereditary ovarian cancer patients may develop secondary tumours in liver and spleen

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

New medical imaging technique using pulsed laser and nanocages

New medical imaging technique using pulsed laser and nanocages

Indispensable role of Mindin in innate and adaptive immunity

Indispensable role of Mindin in innate and adaptive immunity

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

Fundamental step in immune system development discovered

Fundamental step in immune system development discovered

Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV

Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.